ResMed (RMD) Reports In-Line Q1 EPS, Beats on Revenues
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $226.04 -0.31%
Financial Fact:
Cost of sales: 196.27M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Cost of sales: 196.27M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q1 EPS of $0.66, in-line with the analyst estimate of $0.66. Revenue for the quarter came in at $523.7 million versus the consensus estimate of $505.61 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
